Member Info for Zendog

.....keep breathing - who knows , TRP may surprise one day.

..and given the Covid test ended in fiasco and lack of trust in what AVACTA say, must suspect that sentiment is still weighing on the SP. Unfortunately.

~The presentation style is slow / wooden at the start but, overall it's a very positive informative presentation. This company really would seem to be on the cusp of a major step change to serious profitability.

Any access to the presentation now?

There have been so many positive research results about Angle's Parsortix and they got the long awaited FDA approval that may of us thought would be the trigger for solid SP rise.
What will it take to get this SP moving genuinely, robustly upward?

Is there enough potential progress in the existing trials and agreed contracts to get his SP moving genuinely upward by March 2023 or, is some more substantial additional contract award necessary?

One the one hand, great that there's such steady research endorsement of the Parsortix system but on the other hand, really quite worrying for those invested that ANGLE seem unable to capitalise on it.

MCB - the RNS about the poster says the poster slot is 1.30 pm to 5.30 pm on April 11th and AVACTA will be represented by Fiona McLaughlin, PhD, Chief Scientific Officer and Neil Bell, Chief Development Officer (part of RNS copied below):-

So I think you may have wires crossed if you think there is to be some sort of set-piece "presentation" of 9 mins or so at 18:15 pm to some overall audience totally focused on Avacta's "poster".

I think "poster presentation" conferences take the form of conference halls with walk round routes of multiple presenter 'stands' for delegates to walk around look at poster presented on the stands . "Presenters" stand by their poster and talk to delegates who show interest in conversation when looking at the poster? ~Isn't that what this event is?

Poster presentation Title: AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage.

Session Category: Experimental and Molecular Therapeutics

Session Title: Drug Targets

Session Date and Time: Monday Apr 11, 2022 1:30 PM - 5:00 PM CT

Location: New Orleans Convention Center, Exhibit Halls D-H

Abstract Number: #1815

Presenter: Fiona McLaughlin, PhD, Chief Scientific Officer and Neil Bell, Chief Development Officer, Avacta Life Sciences Ltd.

Greedo -
To me, 2.5 months seems more than enough time to find a replacement antibody, if AVACTA was half-serious about re-instating an LFT and recovering some reputation. However, sadly, when it comes to such, the track record is that Avacta is appallingly slow and not particularly aware of how to progress commercially in real time.
Still, we all live in hope that things will change and performance will turn for the better.

Options for Mr Smith
- A very convincing positive (evidenced) RNS
- A real apology for the LFT farce and and explanation of how he is going to improve his company's commercial performance.
- Resignation as CEO

And what became of BAMS and Elisa? Nothing it seems. Just more Smith waffle with no commerciality?

ProfCheese - I think you're right, AVACTA now has a huge credibility issue to overcome. The LFT stands as a company shambles. They urgently need to prove they can reset it to deal with Omicron and show how they will be able to quickly (QUICKLY) adapt to other variants.

Wiggly - I think you may be assuming AS has some commercial acumen. - This may be an assumption with little evidence to back it up.

Chunky - amazing what a glass or two of wine can do. Just dont look at the SP or give a thought to what a shambles the company has been over the LFT.

Valueinv - perhaps they're not buying because they're not confident to buy -given they know what a total balls up they made of the golden opportunity that was the LFT. That balls up doesn't mode well for the Cancer opportunity.

Ash78 - I think you've hit a nail on the head :- Smith is hopeless - seemingly no proactive research preparation or anticipation of requirements or scenario developments. On top of which, he makes misleading optimistic statements which then unravel; he's created the current market loss of confidence - as evidenced by the appalling fall in the shareprice - pretty much single-handedly in respect of his communications ; not least the recent careless comment about the LFT replacement now taking 'some time' after previously suggesting it wouldn't take long. Now , no other way to regard this other than CEO sh_t -show.
But I've already let it my holding slip to having too much loss to sell now, so am stuck with hoping for some sort of recovery via build of positivity around the cancer treatment (which is what I was originally in for).

But the LFT farce does not bode well for Cancer treatment progress and any successful follow through.

Is "pause" equivalent to "shortly" in Avacta-CEO-speak?

Travellight and all

Forgive me I've missed some messages on this BB that have covered this question already but, isn't it possible for Avacta to find a way of making the LFT work such that the whole functionality is governed by Affimers or, at least reagents that are under Avacta control? If not, why not? (If it is possible, it begs the question why haven't they done it already? Maybe that points to it not being possible? [if you assume Aacta are wholly switched on and competent])

Energy - you may be overcomplicating - it is simple isn't it - the SP goes up to the point where sellers exceed buyer, with the spread playing a role in people buy/sell choices.

Phantom, i think you're right. This seems to be a perilous underlying issue for Avacta - was there sufficient honesty in the earlier technical presentations?
~Now that we know the LFT is dependent on an antibody component, do we know who provides this? Is it is under Avacta's control or, are we going into another 12 month process of dependency on a contracted relationship?
How big a problem is it? Avacts's RNS doesn't say anything about whether finding a replacement antibody component is easy, difficult, under there control or dependent on another party.
As seems to happen too often an Avacta RNS raises more questions that it answers?